Hackensack, NJ, June 03, 2010 — The John Theurer Cancer Center at Hackensack University Medical Center announced today that its physicians and researchers will present 16 abstracts on treatment and diagnostic progress in many different areas of oncology during the Annual Meeting of American Society of Clinical Oncology (ASCO) in Chicago, IL from June 4-8.
“At the John Theurer Cancer Center, we’re dedicated to providing extraordinary cancer care to our patients, which includes conducting high-quality cancer research and cutting-edge clinical trials,” said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, the John Theurer Cancer Center. “We’re pleased to add to an important body of research at this premier oncology conference.”
Abstracts from the John Theurer Cancer Center research that are scheduled to be presented include:
- Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM). (8031) (Poster Discussion Session) – Friday, June 4 from 2:00 p.m. – 6:00 p.m. in E450a
- Phase II study of denileukindiftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. (8045) (Poster Discussion Session) – Friday, June 4 from 2:00 p.m. – 6:00 p.m. in E450a
- Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). (8038) (Poster Discussion Session) – Friday, June 4 from 2:00 p.m. – 6:00 p.m. in E450a
- The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC). (8092) (General Poster Session) — Saturday, June 5 from 8:00 am — 12:00 p.m. in S Hall A2
- Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL). (8067) (General Poster Session) — Saturday, June 5 from 8:00 am — 12:00 p.m. in S Hall A2
- Impact of high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03. (10546) (General Poster Session) — Saturday, June 5 from 8:00 am — 12:00 p.m. in S Hall A2
- Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL). (8053) (General Poster Session) — Saturday, June 5 from 8:00 am — 12:00 p.m. in S Hall A2
- Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI). (8135) (General Poster Session) — Saturday, June 5 from 8:00 am — 12:00 p.m. in S Hall A2
- Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). (8078) (General Poster Session) — Saturday, June 5 from 8:00 am — 12:00 p.m. in S Hall A2
- Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study. (8125) (General Poster Session) — Saturday, June 5 from 8:00 am — 12:00 p.m. in S Hall A2
- Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM). (8133) (General Poster Session) — Saturday, June 5 from 8:00 am — 12:00 p.m. in S Hall A2
- Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD. (8006) (Oral Abstract Session) – Saturday, June 5 from 1:00 p.m. — 4:00 p.m. in E354a
- Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study. (8003) (Clinical Science Symposium) Saturday, June 5 from 4:30 p.m. — 6:00 p.m. in E354a
- Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). (8001) (Clinical Science Symposium) Saturday, June 5 from 4:30 p.m. — 6:00 p.m. in E354a
- Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). (8000) (Clinical Science Symposium) Saturday, June 5 from 4:30 p.m. — 6:00 p.m. in E354a
ASCO is the world’s leading professional organization representing physicians who treat those with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer.
About the John Theurer Cancer Center at Hackensack University Medical Center
The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey’s largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancer. The 15 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of after care services that distinguish the John Theurer Cancer Center from other facilities. For more information please go to humccancer.org.
